论文部分内容阅读
目的观察莫西沙星治疗社区获得性肺炎(CAP)的临床疗效。方法 CAP患者85例,分成治疗组和对照组,治疗组42例给予莫西沙星0.4g/d静点7d,后改为口服莫西沙星片0.4g/d 7d序贯治疗;对照组43例给予阿奇霉素注射液0.5g/d静点7d;后改为阿奇霉素片0.5g/d口服7d序贯治疗,疗程均为14d,观察两组的临床疗效及不良反应。结果治疗组总有效率90.47%、痊愈率52.38%,对照组总有效率69.7%、痊愈率34.88%;两组间有统计学意义(P<0.05)。不良反应:治疗组皮疹1例,对照组恶心3例、腹泻2例,症状轻微,对照组1例谷草转氨酶升高,自行好转。结论莫西沙星序贯治疗CAP安全、有效,值得在临床推广应用。
Objective To observe the clinical efficacy of moxifloxacin in the treatment of community-acquired pneumonia (CAP). Methods Eighty-five patients with CAP were divided into treatment group and control group. In the treatment group, 42 patients were given moxifloxacin 0.4g / d intravenously for 7 days and then to oral moxifloxacin tablets 0.4g / d for 7 days. In the control group, 43 patients Given azithromycin injection 0.5g / d static point 7d; later changed to azithromycin 0.5g / d oral 7d sequential treatment, the course of treatment were 14d, the two groups observed the clinical efficacy and adverse reactions. Results The total effective rate was 90.47%, the cure rate was 52.38% in the treatment group, the total effective rate in the control group was 69.7% and the cure rate was 34.88%. There was a significant difference between the two groups (P <0.05). Adverse reactions: 1 case of rash in the treatment group, 3 cases of nausea in the control group, 2 cases of diarrhea, mild symptoms, control group, 1 case of aspartate aminotransferase increased itself improved. Conclusion sequential treatment of moxifloxacin safe and effective, it is worth in the clinical application.